SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc., today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,217,535 covering methods of diagnosing an individual’s susceptibility for developing atherosclerotic disease, including myocardial infarction and stroke, by analyzing a blood sample for lipoprotein-associated phospholipase A2 (Lp-PLA2) enzymatic activity.
